UBS AM’s Sionna Therapeutics SION Stock Holding History

UBS AM’s Portfolio SION Stock Details SION Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$467K	Buy	10,622 +10,506	+9,057%	+$420K	﹤0.01%	2563
2026 Q1	$4.65K	Buy	+116	New	+$4.43K	﹤0.01%	3467

Other funds holding SION

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM's SION Position: Q2 2026 in Review

UBS AM increased its Sionna Therapeutics (SION) stake by 9,057% in Q2 2026, buying an estimated $420K and bringing the position to 10,622 shares worth $467K. The position accounts for ﹤0.01% of the portfolio, ranked #2563.

UBS AM first reported a position in SION in Q1 2026 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

UBS AM held 10,622 shares of Sionna Therapeutics worth $467K as of Q2 2026.
UBS AM bought 10,506 Sionna Therapeutics shares in Q2 2026, an estimated $420K.
Sionna Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2563 holding.
UBS AM first reported a position in Sionna Therapeutics in Q1 2026 and has held it in 2 quarters since.
147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.